2L5J
| structure of the spliceosomal phosphopeptide P140 (phosphorylated form) | Descriptor: | U1 small nuclear ribonucleoprotein 70 kDa | Authors: | Quinternet, M, Page, N, Schall, N, Strub, J, Chaloin, O, Decossas, M, Cung, M, van Dorsselaer, A, Briand, J, Muller, S. | Deposit date: | 2010-11-02 | Release date: | 2010-12-01 | Last modified: | 2011-07-13 | Method: | SOLUTION NMR | Cite: | The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells. Plos One, 4, 2009
|
|
2L5I
| structure of the spliceosomal phosphopeptide P140 (non-phosphorylated form) | Descriptor: | U1 small nuclear ribonucleoprotein 70 kDa | Authors: | Quinternet, M, Page, N, Schall, N, Strub, J, Chaloin, O, Decossas, M, Cung, M, van Dorsselaer, A, Briand, J, Muller, S. | Deposit date: | 2010-11-02 | Release date: | 2010-12-01 | Last modified: | 2011-07-13 | Method: | SOLUTION NMR | Cite: | The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells. Plos One, 4, 2009
|
|
5N9T
| Crystal structure of USP7 in complex with a potent, selective and reversible small-molecule inhibitor | Descriptor: | 3-[4-(aminomethyl)phenyl]-2-methyl-6-[[4-oxidanyl-1-[(3~{R})-4,4,4-tris(fluoranyl)-3-phenyl-butanoyl]piperidin-4-yl]methyl]pyrazolo[4,3-d]pyrimidin-7-one, GLYCEROL, SULFATE ION, ... | Authors: | Harrison, T, Gavory, G, O'Dowd, C, Helm, M, Flasz, J, Arkoudis, E, Dossang, A, Hughes, C, Cassidy, E, McClelland, K, Odrzywol, E, Page, N, Barker, O, Miel, H. | Deposit date: | 2017-02-27 | Release date: | 2017-12-06 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.73 Å) | Cite: | Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. Nat. Chem. Biol., 14, 2018
|
|
5N9R
| Crystal structure of USP7 in complex with a potent, selective and reversible small-molecule inhibitor | Descriptor: | 7-bromanyl-3-[[4-oxidanyl-1-[(3~{R})-3-phenylbutanoyl]piperidin-4-yl]methyl]thieno[3,2-d]pyrimidin-4-one, DIMETHYL SULFOXIDE, GLYCEROL, ... | Authors: | Harrison, T, Gavory, G, O'Dowd, C, Helm, M, Flasz, I, Arkoudis, E, Dossang, A, Hughes, C, Cassidy, E, McClelland, K, Odrzywol, E, Page, N, Barker, O, Miel, H. | Deposit date: | 2017-02-27 | Release date: | 2017-12-06 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (2.23 Å) | Cite: | Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. Nat. Chem. Biol., 14, 2018
|
|
6F5H
| Crystal structure of USP7 in complex with a 4-hydroxypiperidine based inhibitor | Descriptor: | 3-[[4-oxidanyl-1-[(3~{R})-3-phenylbutanoyl]piperidin-4-yl]methyl]-6-(2-pyrrolidin-1-ylethylamino)pyrimidin-4-one, GLYCEROL, SULFATE ION, ... | Authors: | Harrison, T, Gavory, G, O'Dowd, C, Helm, M, Flasz, J, Dossang, A, Hughes, C, Cassidy, E, McClelland, K, Odrzywol, E, Page, N, Barker, O, Miel, H, Feutron-Burton, S, Rountree, J.S.S. | Deposit date: | 2017-12-01 | Release date: | 2018-04-11 | Method: | X-RAY DIFFRACTION (2.16 Å) | Cite: | Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors. ACS Med Chem Lett, 9, 2018
|
|
8Q61
| Co-crystal structure of human AKT2 with compound 3 | Descriptor: | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, 6-[4-(1-azanyl-3-methyl-3-oxidanyl-cyclobutyl)phenyl]-7-phenyl-1-propyl-pyrido[2,3-b][1,4]oxazin-2-one, GLYCEROL, ... | Authors: | Harrison, T, Barker, O. | Deposit date: | 2023-08-10 | Release date: | 2023-08-16 | Method: | X-RAY DIFFRACTION (2.32 Å) | Cite: | Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical development. Sci Rep, 12, 2022
|
|